JPH0717495B2 - Method of manufacturing multi-layered suppository - Google Patents
Method of manufacturing multi-layered suppositoryInfo
- Publication number
- JPH0717495B2 JPH0717495B2 JP32327887A JP32327887A JPH0717495B2 JP H0717495 B2 JPH0717495 B2 JP H0717495B2 JP 32327887 A JP32327887 A JP 32327887A JP 32327887 A JP32327887 A JP 32327887A JP H0717495 B2 JPH0717495 B2 JP H0717495B2
- Authority
- JP
- Japan
- Prior art keywords
- suppository
- layer
- base
- heated
- viscosity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicinal Preparation (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は多層坐剤の製造法に関し、更に詳細には複数の
層が水平に積層れさた多層坐剤の各層を連続充填によつ
て製造する方法に関する。TECHNICAL FIELD The present invention relates to a method for producing a multi-layer suppository, and more specifically, by continuously filling each layer of a multi-layer suppository in which a plurality of layers are laminated horizontally. It relates to a method of manufacturing.
〔従来の技術〕 従来より繁用されている坐剤は、油性基剤、水溶性基
剤、乳剤性基剤等の基剤に一種または二種以上の薬物を
配合し、均一に分散、混和した単層坐剤が一般的であ
る。そしてその製造法は、例えば熔融した油性基剤に薬
物を均一に分散混和したものを、一定量坐剤成形容器に
充填した後冷却するというものである。[Prior Art] Conventionally used suppositories have one or more drugs mixed in a base such as an oily base, a water-soluble base or an emulsion base, and uniformly dispersed and mixed. Single layer suppositories are common. The manufacturing method is, for example, a method in which a drug is uniformly dispersed and mixed in a melted oily base, and a fixed amount of the drug is filled into a suppository molding container and then cooled.
ところで近年、薬効成分の有効利用という観点から各種
の多層坐剤が考案されている。すなわち、多層坐剤にお
ける目的の一つは、複数の薬効成分を坐剤に配合するに
あたり、各々の薬効成分をその薬効発現に最も適した基
剤中に含有せしめることにより、各薬効成分の効果を充
分に発揮させようとするものである。このためには、あ
る薬効成分を含有する層と他の層とは分離した状態で存
在することが必要となる。そしてかかる多層坐剤の製造
法としては、前記単層坐剤の場合と基本的には同じであ
つて、すなわち、加温熔融した基剤を坐剤成形容器に充
填した後、冷却して固形状または半固形状にせしめ、新
たなる基剤を充填積層し、さらに冷却して凝固せしめる
ことを繰り返す方法が知られている(特開昭56-73017
号)。By the way, in recent years, various multilayer suppositories have been devised from the viewpoint of effective use of medicinal components. That is, one of the purposes in a multi-layered suppository is to combine a plurality of medicinal components into a suppository, and to include each medicinal component in the base most suitable for its manifestation of its medicinal properties, thereby producing the effect of each medicinal component. It is intended to make full use of. For this purpose, it is necessary that the layer containing a certain medicinal component and the other layer exist in separate states. The method for producing such a multi-layer suppository is basically the same as that for the above-mentioned single-layer suppository, that is, after filling the suppository molded container with the heated and melted base, it is cooled and solidified. There is known a method of repeating the steps of forming into a shape or a semi-solid state, filling and laminating with a new base material, and further cooling and solidifying (JP-A-56-73017).
issue).
しかしながら従来の多層坐剤の製造法においては、一層
充填する毎に冷却操作を必要とし、さらに製造された坐
剤には保存温度、時間により積層された基剤の混和、他
層への薬効成分の移行等の問題があつた。またかかる問
題は、最近坐剤に要求される種々の機能、すなわち、徐
放化坐剤、直腸下部滞留性坐剤等の開発の障害となつて
いた。However, in the conventional method for producing a multi-layered suppository, a cooling operation is required every time one layer is filled, and the produced suppository has a mixture of the bases laminated depending on the storage temperature and the time, and the medicinal ingredients for other layers. There was a problem such as the migration. Further, such a problem has been an obstacle to development of various functions recently required for suppositories, that is, sustained-release suppositories, suppositories having a lower portion of the rectum, and the like.
そこで本発明者はかかる問題点を解決すべく種々検討し
てきたところ、油性基剤に粘度を高める処理を施すこと
により、多層坐剤の各層の積層を熔融温度以上で連続的
に充填することができ、さまざまな用途に応じた機能を
もつ多層坐剤の製造が可能となることを見い出し本発明
を完成した。Therefore, the present inventor has conducted various studies to solve such problems, and it is possible to continuously fill the laminate of each layer of the multilayer suppository at a melting temperature or higher by subjecting the oily base to a treatment for increasing the viscosity. It has been found that it is possible to produce a multi-layered suppository having a function according to various uses, and completed the present invention.
すなわち、本発明は複数の層が水平に積層された多層坐
剤を製造するにあたり、各層を形成する常温で固形状の
油性基剤を加温熔融し、最終層以外の層について温度40
℃における粘度が1万〜100万cpとなるように調整し、
また最終層については粘度を上記と同様に調整するか、
もしくは調整せずに、該基剤を熔融温度以上の温度にお
いて坐剤成形容器に連続的に充填した後、全体を冷却し
凝固せしめることを特徴とする多層坐剤の製造法を提供
するものである。That is, in the present invention, in producing a multi-layered suppository in which a plurality of layers are laminated horizontally, a solid oily base that forms each layer is heated and melted at a temperature of 40 degrees for layers other than the final layer.
Adjust the viscosity at ℃ to be 10,000 to 1,000,000 cp,
For the final layer, adjust the viscosity as above, or
Alternatively, without any adjustment, a suppository molding container is continuously filled with the base at a temperature equal to or higher than the melting temperature, and then the whole is cooled and solidified to provide a method for producing a multilayer suppository. is there.
本発明に用いられる基剤は、常温で固形状であつて油性
であれば特に制限されないが、例えばカカオ脂、ラノリ
ン脂、イソカカオ (花王製)、ウイテプゾル (ダイ
ナミツクノーベル社製)、サポシア (ガツテフオツセ
社)、SB (鐘渕化学工業製)、フアーマゾル (日本
油脂製)等の局外規ハードフアツトが挙げられる。The base used in the present invention is solid at room temperature and oily.
It is not particularly limited as long as it is, for example, cocoa butter, lanolin
Fat, isocaca (Made by Kao), Witepsol (Die
Namitsu Nobel), Saposia (Gatsutte Otsuse
Company), SB (Made by Kanebuchi Chemical Industry), Fuamasol (Japan
For example, an external regulation hard fat such as oil and fat) can be used.
本発明に用いられる薬効成分としては、痔疾用坐剤とし
てヒドロコルチゾン、酢酸ヒドロコルチゾン等のステロ
イド;塩酸ジブカイン、塩酸プロカイン、リドカイン等
の局所麻酔剤;グリチルレチン酸、グリチルリチン酸ジ
カリウム、アラントイン等の抗炎症剤;塩酸クロルヘキ
シジン、セトリシド等の殺菌剤;パルミチン酸レチノー
ル、dl-α‐トコフエロール等のビタミン剤などがあげ
られ、解熱鎮痛・消炎用坐剤としてアスピリン、サリチ
ル酸ナトリウム、インドメタシン、オキシフエンブタゾ
ン等があげられ、抗生物質、化学療法用坐剤としてペニ
シリンGナトリウム、クロラムフエニコール、フアンギ
ゾン、スルフアジメトキシンや各種サルフア剤などがあ
げられるがここにあげたものに限定されないことはいう
までもないこどである。The medicinal components used in the present invention include steroids such as hydrocortisone and hydrocortisone acetate for hemorrhoids; local anesthetics such as dibucaine hydrochloride, procaine hydrochloride and lidocaine; anti-inflammatory agents such as glycyrrhetinic acid, dipotassium glycyrrhizinate and allantoin; Examples include bactericides such as chlorhexidine hydrochloride and cetricid; retinol palmitate and vitamins such as dl-α-tocopherol. Examples of suppositories for antipyretic analgesia and anti-inflammatory include aspirin, sodium salicylate, indomethacin, oxyphenbutazone and the like. , Antibiotics, suppositories for chemotherapy, penicillin G sodium, chloramphenicol, fangizone, sulfadimethoxine, and various sulfa drugs, but it goes without saying that they are not limited to these. Ah .
本発明における粘度を高める処理は、基本的には増粘剤
の添加により行なわれる。The treatment for increasing the viscosity in the present invention is basically performed by adding a thickener.
用いる増粘剤としては軽質無水ケイ酸、ステアリン酸の
アルミニウム塩、カルシウム塩、バリウム塩もしくはマ
グネシウム塩、12−ヒドロキシステアリン酸、D−ソル
ビトールとベンズアルデヒドの縮合物〔例えば、ゲルオ
ールD(新日本理化社製)〕、デキストリン脂肪酸エス
テル〔例えば、レオパールKE(千葉製粉社製)〕、スチ
レン−エチレン−ブチレン−スチレン重合体〔例えば、
SEBS(シエル化学社製)〕、有機性ベントナイト等が挙
げられる。Examples of thickeners used include light anhydrous silicic acid, aluminum salts of stearic acid, calcium salts, barium salts or magnesium salts, 12-hydroxystearic acid, condensates of D-sorbitol and benzaldehyde [eg, Gelol D (Shin Nippon Rika Co., Ltd. Manufactured), dextrin fatty acid ester [for example, Leopard KE (manufactured by Chiba Flour Milling Co.)], styrene-ethylene-butylene-styrene polymer [for example,
SEBS (manufactured by Ciel Chemical Co., Ltd.)], organic bentonite, and the like.
本発明を実施するにはまず上記油性基剤を加温熔融した
ものに必要な薬効成分及び増粘剤を添加し、均一に分散
せしめる。増粘剤は、その種類によつても異なるが1〜
50重量%、特に5〜10重量%の範囲で、40℃における粘
度が1万〜100万cpとなるように調整して添加するのが
好ましい。In order to carry out the present invention, first, the necessary medicinal components and a thickening agent are added to a product obtained by heating and melting the above-mentioned oily base and uniformly dispersed. Thickeners vary depending on their type, but 1 to
It is preferable to add it in a range of 50% by weight, particularly 5 to 10% by weight so that the viscosity at 40 ° C. is 10,000 to 1,000,000 cp.
次いで得られた熔融基剤を坐剤成形容器に充填し、さら
に熔融基剤を連続的に充填した後、全体を冷却して凝固
せしめることにより多層坐剤が製造される。Next, a multi-layered suppository is manufactured by filling the obtained suppository base into a suppository forming container, continuously filling the suppository base, and then cooling and solidifying the whole.
本発明方法において、最終層を形成する油性基剤におい
ては必ずしも粘度を高める処理を施す必要はない。In the method of the present invention, the oily base forming the final layer does not necessarily have to be subjected to a treatment for increasing the viscosity.
本発明によつて複数の層が水平に積層された多層坐剤
を、油性基剤を熔融温度以上の温度において連続的に充
填して製造することが可能となつた。従つて、製造時の
操作が極めて容易になつたことに加え、熔融温度におい
ても各層が混和せず、複数の薬効成分をその薬効発現に
最も適した基剤中に含有せしめることが可能となり、さ
らに最近坐剤に要求される種々の機能、例えば徐放化坐
剤、直腸下部滞留性坐剤等の機能を持たせることが可能
となつた。According to the present invention, it is possible to manufacture a multi-layered suppository in which a plurality of layers are laminated horizontally by continuously filling an oily base at a temperature equal to or higher than the melting temperature. Therefore, in addition to the fact that the operation during manufacturing is extremely easy, the respective layers do not mix even at the melting temperature, and it becomes possible to include a plurality of medicinal components in the base most suitable for exhibiting their medicinal effects. Furthermore, it has recently become possible to provide various functions required for suppositories, such as a sustained release suppository and a lower rectal retention suppository.
次に実施例を挙げて本発明を詳細に説明する。 Next, the present invention will be described in detail with reference to examples.
実施例1 局外規ハードフアツト(イソカカオKD35)を50℃に加温
熔融し、これに軽質無水ケイ酸(Aerosil 200,日本アエ
ロジル(株))を1〜7重量%添加し、ホモミキサーを
用いて十分混合した。これを2g充填用坐剤成形容器(透
明容器)に1g充填した。別途局外規ハードフアツト(イ
ソカカオKD35)を50℃に加温熔融し、これに着色剤とし
てグアイアズレンを1重量%添加して調製したもの1gを
前記容器に続けて充填積層し、基剤の混和性を肉眼で観
察した。Example 1 An extra-standard hard fat (Isocacao KD35) was heated and melted at 50 ° C., and 1 to 7% by weight of light silicic anhydride (Aerosil 200, Nippon Aerosil Co., Ltd.) was added thereto and a homomixer was used. Mixed well. 1 g of this was filled in a suppository molding container for filling 2 g (transparent container). Separately, an extra-standard hard fat (Isocacao KD35) was heated and melted at 50 ° C, and 1 g of guaiazulene as a coloring agent was added to the container to prepare 1 g, which was continuously filled and laminated to mix the base materials. Was visually observed.
評価基準 A:基剤の混和を認めず積層が可能。Evaluation Criteria A: Can be laminated without admixture of base materials.
B:基剤の一部が混和し水平に積層できない。B: A part of the base is mixed and cannot be stacked horizontally.
C:全体が均一に混和し積層が不可能。C: The whole mixture is uniformly mixed and cannot be laminated.
実施例2 1回目充填基剤の油性基剤に増粘剤を添加し、穏やかに
分散し、充填した後、超音波処理(発振周波数45KHz,高
周波出力60W)を30分行なう以外は実施例1と同様の操
作を行ない、積層状態を評価した。 Example 2 Example 1 except that a thickening agent was added to the oily base of the first filling base, gently dispersed and filled, and then ultrasonication (oscillation frequency 45 KHz, high frequency output 60 W) was performed for 30 minutes. The same operation as above was performed to evaluate the laminated state.
結果を表2に示す。The results are shown in Table 2.
Claims (1)
造するにあたり、各層を形成する常温で固形状の油性基
剤を加温熔融し、最終層以外の層について温度40℃にお
ける粘度が1万〜100万cpとなるように調整し、また最
終層については粘度を上記と同様に調整するか、もしく
は調整せずに、該基剤を熔融温度以上の温度において坐
剤成形容器に連続的に充填した後、全体を冷却し凝固せ
しめることを特徴とする多層坐剤の製造法。1. When manufacturing a multi-layer suppository in which a plurality of layers are laminated horizontally, a solid oily base which forms each layer is heated and melted, and the layers other than the final layer are heated at a temperature of 40 ° C. The suppository molding container is adjusted to have a viscosity of 10,000 to 1,000,000 cp, and for the final layer, the viscosity is adjusted in the same manner as above, or is not adjusted, and the base is heated at a melting temperature or higher. A method for producing a multi-layer suppository, which comprises continuously filling and then solidifying by cooling.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32327887A JPH0717495B2 (en) | 1987-12-21 | 1987-12-21 | Method of manufacturing multi-layered suppository |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32327887A JPH0717495B2 (en) | 1987-12-21 | 1987-12-21 | Method of manufacturing multi-layered suppository |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01163117A JPH01163117A (en) | 1989-06-27 |
JPH0717495B2 true JPH0717495B2 (en) | 1995-03-01 |
Family
ID=18153004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP32327887A Expired - Lifetime JPH0717495B2 (en) | 1987-12-21 | 1987-12-21 | Method of manufacturing multi-layered suppository |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0717495B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021060841A1 (en) * | 2019-09-23 | 2021-04-01 | 연세대학교 산학협력단 | Novel multilayer suppository agent |
-
1987
- 1987-12-21 JP JP32327887A patent/JPH0717495B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021060841A1 (en) * | 2019-09-23 | 2021-04-01 | 연세대학교 산학협력단 | Novel multilayer suppository agent |
Also Published As
Publication number | Publication date |
---|---|
JPH01163117A (en) | 1989-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3440320A (en) | Chelated suppository and method of using same | |
Baviskar et al. | Drug delivery on rectal absorption: suppositories | |
PT1064935E (en) | Solid controlled-release pharmaceutical compositions prepared by means of a thermoforming process | |
JP2004534833A (en) | Oral pharmaceutical composition with improved active ingredient release ability | |
WO2007017331A2 (en) | Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin | |
JPH066530B2 (en) | Drug-containing suppository | |
JPS62174008A (en) | Suppository base and suppository | |
JPH0717495B2 (en) | Method of manufacturing multi-layered suppository | |
JP2004534832A (en) | Oral pharmaceutical compositions with enhanced bioavailability | |
US3325472A (en) | Polycyclohexose-polyoxyethyleneglycol suppository bases | |
KR20120104604A (en) | Mesalamine suppository | |
JP2000513334A (en) | Topical anti-vaginitis composition comprising one or more anti-vaginitis agents and one or more local anesthetics | |
Kocabas et al. | 3D-printed prednisolone phosphate suppositories with tunable dose and rapid release for the treatment of inflammatory bowel disease | |
JPH01163118A (en) | Multi-layer suppository | |
JP2003266519A5 (en) | Method of producing polyester film | |
Wilkin | Flushing reactions in the cancer chemotherapy patient: the lists are longer but the strategies are the same | |
US3622673A (en) | 4-(1,4,5,6-TETRAHYDROZEPINO 4,5-b INDOL-3(2H)-YL-BUTYROPHENON COMPOSITIONS AND PROCESS OF TREATMENT MENTAL OR EMOTIONAL DISORDERS | |
DE1770944A1 (en) | Process for the preparation of benzodiazepine derivatives | |
Rimsza | Counseling the adolescent about contraception | |
Brunaugh et al. | Rectal and Vaginal Drug Delivery | |
US3060090A (en) | Pyrazolidine-quinazolone therapeutic composition | |
JPS59101420A (en) | Rectal composition containing indomethacin | |
US2807568A (en) | Therapeutic compositions of tetracycline group antibiotic and parahydroxybenzoic acid ester | |
Oulali | Biopharmaceutical studies of the influence of pharmaceutical factors on the quality indicators of extemporaneouse suppositories | |
RU2122851C1 (en) | Suppository showing antiinflammatory and wound-healing effect |